LearnGlossaryMarketStocksSuperinvestorsSign in

ZYME

Zymeworks Inc.

Healthcare · $2.0B market cap

Verdict

We can't put a fair value on ZYME right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

2 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-9.5% a year✗
Sales growth25.0% a year✓
Free cash flow growth58.5% a year✓
Return on invested capital-30.8%✗

Follow ZYME

Track it on your watchlist and see the full analysis. Free.

Create a free account

About Zymeworks Inc.

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works